, Dec. 13, 2013
/PRNewswire/ -- The first Esteya® electronic brachytherapy system
in the United States
has been installed at New York's
Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.
"With support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study with the goal to further improve skin cancer treatment," says John Lapre, Executive Vice President, Elekta Brachytherapy. "With its leading role at the forefront of brachytherapy research, the hospital will help advance the quality of patient care and add to the evidence base that caregivers need for their clinical decisions."
Esteya features an efficient workflow, easy patient set-up, and a short, less than three-minute, treatment delivery. The system's compact design and reduced shielding requirements also make treatment with Esteya highly accessible, enabling clinicians to treat lesions virtually anywhere patients are seen in the clinic.
For more information about Esteya, visit www.esteya.com.
Availability of Esteya in identified markets is subject to regulatory approvals.
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.